Voyager Therapeutics Inc. never intended to give up its US rights to the Parkinson's disease candidate VY-AADC01 under its collaboration agreement with Sanofi, but now the company says that was a deal-breaker for its partner, which returned its ex-US rights to the gene therapy.
Voyager retained US rights to its lead product candidate when it negotiated a three-program deal with Sanofi in 2015. Even...








